生物制剂与骨质流失
Biologicals and bone loss.
机构信息
Department of Rheumatology, Jan van Breemen Research Institute/Reade, Amsterdam, The Netherlands.
出版信息
Ther Adv Musculoskelet Dis. 2012 Aug;4(4):245-7. doi: 10.1177/1759720X12441275.
Abstract
Inflammatory joint diseases are associated with extra-articular side effects including bone involvement.There is an increased risk of osteoporotic fractures. The pathogeneses of local and generalized bone loss share a common pathway. Early and active rheumatoid arthritis is associated with longitudinal observed bone loss and fracture rate is of vertebral and nonvertebral fractures is doubled compared with matched healthy controls. Lowering disease activity with TNF inhibitors or is associated with stabilisation of bone mineral density by counteracting elevated bone resorption.
摘要
炎性关节病与包括骨骼受累在内的关节外副作用相关。存在骨质疏松性骨折风险增加。局部和全身性骨质流失的发病机制具有共同途径。早期和活跃的类风湿关节炎与纵向观察到的骨质流失有关，与匹配的健康对照组相比，椎体和非椎体骨折的发生率增加了一倍。使用 TNF 抑制剂降低疾病活动度与通过对抗骨吸收增加来稳定骨矿物质密度有关。
相似文献
1
Biologicals and bone loss.
Ther Adv Musculoskelet Dis. 2012 Aug;4(4):245-7. doi: 10.1177/1759720X12441275.
2
Osteoporosis in rheumatoid arthritis and ankylosing spondylitis.
Clin Exp Rheumatol. 2009 Jul-Aug;27(4 Suppl 55):S62-7.
3
Osteoporosis in inflammatory joint diseases.
Osteoporos Int. 2011 Feb;22(2):421-33. doi: 10.1007/s00198-010-1319-x. Epub 2010 Jun 15.
4
Management of osteoporosis in rheumatoid arthritis patients.
Expert Opin Pharmacother. 2015 Mar;16(4):559-71. doi: 10.1517/14656566.2015.997709. Epub 2015 Jan 27.
5
Higher Level of Dickkopf-1 is Associated with Low Bone Mineral Density and Higher Prevalence of Vertebral Fractures in Patients with Ankylosing Spondylitis.
Calcif Tissue Int. 2016 May;98(5):438-45. doi: 10.1007/s00223-015-0093-3. Epub 2015 Dec 8.
7
Effects of 1-year anti-TNF-α therapies on bone mineral density and bone biomarkers in rheumatoid arthritis and ankylosing spondylitis.
Clin Rheumatol. 2020 Jan;39(1):167-175. doi: 10.1007/s10067-019-04771-3. Epub 2019 Sep 14.
8
Prevalence of osteoporosis and vertebral fractures and related factors in patients with ankylosing spondylitis.
Chin Med J (Engl). 2014;127(15):2740-7.
9
Long-Term Treatment With TNF-Alpha Inhibitors Improves Bone Mineral Density But Not Vertebral Fracture Progression in Ankylosing Spondylitis.
J Bone Miner Res. 2019 Jun;34(6):1041-1048. doi: 10.1002/jbmr.3684. Epub 2019 Mar 25.
10
Bone Mineral Density and Fracture Risk in Ankylosing Spondylitis: A Meta-Analysis.
Calcif Tissue Int. 2017 Aug;101(2):182-192. doi: 10.1007/s00223-017-0274-3. Epub 2017 Apr 18.
引用本文的文献
1
Yougui pills prevent ovariectomy-induced bone loss by suppressing Th17 response and IL-17/NF-κB pathway.
Ann Med. 2025 Dec;57(1):2529576. doi: 10.1080/07853890.2025.2529576. Epub 2025 Jul 7.
2
C-reactive protein and risk of fracture: a systematic review and dose-response meta-analysis of prospective cohort studies.
Osteoporos Int. 2015 Jan;26(1):49-57. doi: 10.1007/s00198-014-2826-y. Epub 2014 Aug 9.
3
Dissecting the relationship between high-sensitivity serum C-reactive protein and increased fracture risk: the Rotterdam Study.
Osteoporos Int. 2014 Apr;25(4):1247-54. doi: 10.1007/s00198-013-2578-0. Epub 2013 Dec 13.
本文引用的文献
1
Suppression of bone turnover by B-cell depletion in patients with rheumatoid arthritis.
Osteoporos Int. 2011 Dec;22(12):3067-72. doi: 10.1007/s00198-011-1607-0. Epub 2011 Apr 6.
2
The change of bone mineral density according to treatment agents in patients with ankylosing spondylitis.
Joint Bone Spine. 2011 Mar;78(2):188-93. doi: 10.1016/j.jbspin.2010.05.010.
3
Stable bone mineral density in lumbar spine and hip in contrast to bone loss in the hands during long-term treatment with infliximab in patients with rheumatoid arthritis.
Ann Rheum Dis. 2011 Feb;70(2):389-90. doi: 10.1136/ard.2009.127787. Epub 2010 May 6.
4
Bone remodeling in rheumatic disease: a question of balance.
Immunol Rev. 2010 Jan;233(1):301-12. doi: 10.1111/j.0105-2896.2009.00857.x.
5
How antirheumatic drugs protect joints from damage in rheumatoid arthritis.
Arthritis Rheum. 2008 Oct;58(10):2936-48. doi: 10.1002/art.23951.
6
Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss.
Ann Rheum Dis. 2009 Mar;68(3):373-6. doi: 10.1136/ard.2008.091611. Epub 2008 Apr 13.
7
Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis.
Arthritis Rheum. 2006 Oct;54(10):3104-12. doi: 10.1002/art.22117.
8
Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis.
Ann Rheum Dis. 2006 Nov;65(11):1495-9. doi: 10.1136/ard.2005.044198. Epub 2006 Apr 10.
9
Vertebral deformities in rheumatoid arthritis: a comparison with population-based controls.
Arch Intern Med. 2004 Feb 23;164(4):420-5. doi: 10.1001/archinte.164.4.420.
10
Osteoclast differentiation and activation.
Nature. 2003 May 15;423(6937):337-42. doi: 10.1038/nature01658.
Zotero 插件